Acute Myelogenous Leukemia

P1/2, N=40, Recruiting, Guangdong Second Provincial General Hospital

P1, N=50, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jun 2026 --> Sep 2026

P1, N=30, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Sep 2026 --> Dec 2029

P2, N=216, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting

The patient received standard induction chemotherapy followed by consolidation therapy according to conventional AML protocols. This case highlights the importance of integrating cytomorphology, immunophenotyping, and cytogenetic findings to establish the correct diagnosis when atypical histiocytic-like features are present.

Although these findings required an urgent repeat marrow evaluation, cytogenetic/molecular testing, and hematology clearance due to the high risk of an indeterminate or pre-leukemic state, the presence of active, refractory gastrointestinal bleeding prompted the immediate initiation of infliximab induction...Severe systemic inflammation can create a reactive bone marrow phenotype indistinguishable from early myeloid neoplasia or myelodysplastic syndrome, posing a life-threatening diagnostic trap. Comprehensive hematologic evaluation-including repeat bone marrow assessment under controlled inflammatory conditions-should be considered mandatory before initiating biologic therapy in patients with CD and unexplained cytopenias or borderline blast counts.

This selected real-world cohort demonstrates durable responses exceeding published benchmarks and has one of the longest follow-up periods reported for IDHi in AML. A subset of older adults with IDH-mutated AML can achieve highly durable remissions on IDHi without significant toxicity.

The combination significantly prolonged survival in AML-bearing mice and produced no notable toxicity to major organs, hematologic parameters, or liver and kidney function tests. In summary, combination therapy with FeNPs and miGBA achieves potent anti-AML efficacy with favorable in vivo safety, and has potential for clinical development.

Our study demonstrates that lysosome-associated signature might forecast the prognosis of AML patients and offer guidance for subsequent immunotherapy and chemotherapy strategies.

Intestinal BA elevates hepatic GCA levels. GCA binds to TGR5 and upregulates FOSL1. This subsequently downregulates CD95 transcription and inhibits CD95-mediated hepatocyte apoptosis, thereby alleviating ConA-induced liver injury. This study elucidates the molecular mechanism by which BA modulates CD95-dependent hepatocyte apoptosis via GCA, providing a molecular foundation for exploring the protective role of BA in CD95-associated liver diseases.